Volume 1 Issue 1
2017-08-29 Research Article
Abstract
Background: Hypoparathyroidism is well known to occur in thalassemia major patients, but it is thought to be uncommon and its incidence is considered to be decreasing with improvements in chelation therapy. The objective of this study was to assess the prevalence of parathyroid dysfunction in the first decade of life of the patients with thalassemia major.
Patients and Methods: Ninety children with beta-thalassemia major (55 males and 35 females) with a mean age of 7.17±3.78 years (1-13 years) and age and sex matched control group of 60 healthy children (36 males and 24 females) with a mean age 6.98±3.66 years (1-13) years. Serum parathyroid hormone (PTH), serum total Calcium (Ca), serum phosphorus (P), serum alkaline phosphatase (ALP), serum 25-hydroxyvitamin D (25-OHD) and serum ferritin levels were measured.
Result: PTH levels were higher than normal range in 23 (25.6%) patients with a mean value of 75.2±31.3 µg/mL compared to those having normal range level (35.3±15.2 µg/mL). Ca levels were found low in 11 patients (12.2%), and P levels were found high in 2 (2.22%) and low in 4 (4.44%) patients while high ALP levels were found in 6 (6.67%) patients. 25-OHD levels were low in all patients with a mean value of 24.95±5.82.
Conclusion: Reports in the literature indicate that parathyroid dysfunction due to iron overload generally occurs in 2nd or 3rd decade of patients with thalassemia major. However, our study shows that PTH due to iron overload may develop in a significant number of thalassemia major patients, therefore, all thalassemics should be carefully watched for endocrine organ function such as hyperparathyroidism might occur even in the first decade of the patients with thalassemia major.
Abstract Read Full Article HTML DOI: 10.29328/journal.hcem.1001003 Cite this Article
2017-08-04 Research Article
Abstract
Background: Vitamin D deficiency in pregnancy increases several risks of breastfed mothers. To prevent these adverse events, vitamin D supplementation during pregnancy and lactation is recommended, but suggested dose ranges vary.
Objective: To determine whether vitamin D3 1,800 IU/d supplementation in lactating mothers improves the vitamin D status of their breastfed infants.
Materials and Methods: A randomized, placebo–controlled trial with Thai pregnant women was conducted. Lactating mothers (n=72) and their breastfed infants with insufficient maternal 25 hydroxyvitamin D (25(OH)D) levels in the third trimester were randomly assigned to two groups, one of which received 1,800 IU/d vitamin D supplementation and the other a placebo. Maternal serum 25(OH)D during lactation, cord blood, and 6-week breastfed infant serum were measured using LC-MS/MS.
Results: Mean maternal age (±SD) was 27±5 years, and pre-gestational BMI was 22.29±5 kg/m2. Maternal serum 25(OH)D at baseline was 22.29±7.15 nmol/L. At 6 weeks, both maternal 25(OH)D and infant 25 (OH)D levels had increased significantly in the vitamin D supplement group of mothers and infants (68.30±15.40, 40.40±12.56 nmol/L) compared to those in placebo groups (55.15±13.57, 24.28±17.20 nmol/L) (p <0.001, p<0.001). The changes in infant 25(OH)D levels increased substantially in the vitamin D supplement group but decreased in placebo(17.49±16.27 ng/ml compared to -1.34±19.23 nmol/L in the placebo group, p<0.001). The change of maternal 25(OH)D were positively correlation to the change of 25(OH)D level in breastmilk mothers and infants by r=0.697, p<0.001 and r=0.379, p=0.003 respectively.
Conclusions: Vitamin D3 supplementation to breastfed mother during lactation can increase serum 25(OH)D level in Thai breastfed mother and infants. Further work is needed to determine the optimum duration of vitamin D supplementation to normalized breastfed infants with 25(OH)D level >75 nmol/L.
Abstract Read Full Article HTML DOI: 10.29328/journal.hcem.1001002 Cite this Article
2017-03-15 Case Report
Abstract
Introduction: Lipoprotein (a) [Lp(a)] is a marker for cardiovascular disease, involved in pathogenesis and progression of atherosclerosis. In selected high-risk patients, lipoprotein-apheresis could optimize secondary prevention and improve prognosis.
Aim: We presented the case of a 49-year-old man with high lipoprotein (a) levels and recurrent cardiac adverse events, despite maximal pharmacological therapy.
Case report: Four years before the admission at our Centre, he presented an anterior STEMI, treated with angioplasty and implantation of a drug eluting stent on left anterior descending artery, at the age of 47 years, in September 2012; one month later, the patients presented a new episode of angina, and exams showed a critical stenosis in the right coronary artery, treated by angioplasty and implantation of drug eluting stent. Because of high Lp(a) plasma levels, patient was subsequently on regularly 7-10 day lipoprotein apheresis.
Results and discussion: A thrombophilic screening was performed, showing the simultaneous presence of heterozygous V Leiden mutation and prothrombin G20210A mutation. He referred to our Centre in order to optimize therapy; we performed an endothelial function assessment showing a severe dysfunctional pattern.
Because of these findings, we prescribed dual antiplatelet therapy, and we added omega-3 fatty acids and association with nicotinic acid/laropiprant. According with current guidelines, considering the high risk of bleeding, we preferred not to administer anticoagulant therapy. At 6-month and 1-year follow up the patient continued lipoprotein apheresis and was asymptomatic for other cardiovascular events.
Conclusions: The assessment for the eventual presence of thrombophilia might become a useful tool in clinical practice for high-risk selected patients.
Abstract Read Full Article HTML DOI: 10.29328/journal.hcem.1001001 Cite this Article
Recent Articles
2021-07-31 Letter to the Editor
Yuichi Takashi* and Daiji Kawanami*
Abstract Read Full Article HTML DOI: 10.29328/journal.acem.1001021 Citation
2021-04-07 Research Article
Laura Capdevila, Ariadna Borrà s, Eugenio Berlanga, Judith Sánchez- Manubens, Josefa Rivera and Raquel Corripio*
Abstract Read Full Article HTML DOI: 10.29328/journal.acem.1001020 Citation
2021-03-01 Research Article
Hacer Efnan Melek, Ayça Törel Ergür* and Gökçe Kaan Ataç
Abstract Read Full Article HTML DOI: 10.29328/journal.acem.1001019 Citation
2021-02-16 Case Report
George H Sakorafas*
Abstract Read Full Article HTML DOI: 10.29328/journal.acem.1001018 Citation
2021-01-19 Research Article
Martin Galindo, Katrina M Schrode and Magda Shaheen*
Abstract Read Full Article HTML DOI: 10.29328/journal.acem.1001017 Citation
2020-07-27 Case Report
Zeilberger MS*, Hasmann SE*, Auer MK and Schmidmaier R
Abstract Read Full Article HTML DOI: 10.29328/journal.acem.1001016 Citation
2020-05-27 Opinion
Nicolina Di Biase*
Abstract Read Full Article HTML DOI: 10.29328/journal.acem.1001015 Citation
2020-05-21 Research Article
Snobia Munir*, Samreen Riaz, Tooba Arshad and Aasma Riaz
Abstract Read Full Article HTML DOI: 10.29328/journal.acem.1001014 Citation
2020-04-29 Case Report
Gul Bano*, Claudette Phillips, Sarah Tang, Anup Sharma and Nigel Beharry
Abstract Read Full Article HTML DOI: 10.29328/journal.acem.1001013 Citation
2020-02-28 Review Article
Snobia Munir* and Samreen Riaz
Abstract Read Full Article HTML DOI: 10.29328/journal.acem.1001012 Citation